Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluation of safety and tolerability of pirfenidone in asbestosis
2018-001781-41Phase 2Active
- Sponsor
- NVALT
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pirfenidone in asbestosis, sponsored by NVALT. Primary endpoint: Safety and tolerability (weekly digital symptom and AE score). Started Nov 2018; status: active.
02
Drugs
pirfenidone
03
Conditions
asbestosis
Beyond the preview
Go deeper on 2018-001781-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001781-41.